Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT3001 in acute ischemic stroke
NCT04091945Phase 2Completed
- Sponsor
- Lumosa Therapeutics
- Start
- Jan 2020
- Primary completion
- Feb 2021
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of odatroltide in ischemic stroke, sponsored by Lumosa Therapeutics. Started Jan 2020; status: completed.
02
Drugs
odatroltide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04091945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091945.